MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Are Drug-Eluting Stents in Trouble?

Doctors are using drug-eluting stents less and turning to their bare metal counterparts more often, according to consulting firm Goodroe Healthcare Solutions LLC. Part of this could be due to studies that have revealed a potential link between bloot clots and drug-eluting stents. The Boston Globe reports that although the shift is small, it could still hurt the revenues of companies like Boston Scientific and Johnson & Johnson.

It mentions that Boston Scientific informed Wall Street that its stent sales for the third quarter of 2006 could drop as much as $50 million from the previous year. Johnson & Johnson's rival Cypher stent also saw a decrease in third quarter sales--down six percent from the same quarter last year, and it's international sales fell three percent.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.